Prognostic Model of Typical Complications Caused by Transcatheter Aortic Valve Replacement

Ovcharenko E.A., Klyshnikov K.U., Ganyukov V.I., Shilov A.A., Vereshchagin I.E., Sizova I.N., Tarasov R.S., Barbarash L.S.

Key words: transcatheter aortic valve replacement; cardiac conduction disturbances; paraprosthetic regurgitation; discriminant analysis.

2020, volume 12, issue 2, page 27.

DOI: https://doi.org/10.17691/stm2020.12.2.03

Full text

html pdf

2112

1370

Abstract
References
How to cite

The aim of the study was to develop a prognostic model based on statistical discriminant analysis to assess the risk of postoperative disturbance of cardiac conduction and paraprosthetic regurgitation after transcatheter aortic valve replacement (TAVR).

Materials and Methods. Clinical data of 10 patients implanted with CoreValve^ТМ prostheses (Medtronic Inc., USA) were used to develop prognostic models. To that end, we analyzed changes in hemodynamic and functional parameters provided by echocardiography in the pre- and postoperative periods.

Results. We observed significant positive changes in the severity of left ventricular myocardial hypertrophy; on the contrary, volume indicators did not significantly change, which might be associated with the concentric type of left ventricular hypertrophy. The discriminant analysis made it possible to determine major (preoperative) morphological and functional indicators associated with the two most common complications of the procedure: left bundle branch block and paraprosthetic regurgitation. Left ventricular posterior wall thickness, interventricular septal thickness, left atrium dimension, and myocardial mass are the critical factors that determine the development of these complications.

Conclusion. In the prognostic model, the proposed weighting coefficients allow one to assess the risk of postoperative complications; however, the presence of false-positive results requires further refinement of these coefficients within the linear equation.

Baumgartner H., Falk V., Bax J.J., De Bonis M., Hamm C., Holm P.J., Iung B., Lancellotti P., Lansac E., Rodriguez Muñoz D., Rosenhek R., Sjögren J., Tornos Mas P., Vahanian A., Walther T., Wendler O., Windecker S., Zamorano J.L.; ESC Scientific Document Group. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2017; 38(36): 2739–2791, https://doi.org/10.1093/eurheartj/ehx391.
Leon M.B., Smith C.R., Mack M.J., Makkar R.R., Svensson L.G., Kodali S.K., Thourani V.H., Tuzcu E.M., Miller D.C., Herrmann H.C., Doshi D., Cohen D.J., Pichard A.D., Kapadia S., Dewey T., Babaliaros V., Szeto W.Y., Williams M.R., Kereiakes D., Zajarias A., Greason K.L., Whisenant B.K., Hodson R.W., Moses J.W., Trento A., Brown D.L., Fearon W.F., Pibarot P., Hahn R.T., Jaber W.A., Anderson W.N., Alu M.C., Webb J.G.; PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016; 374(17): 1609–1620, https://doi.org/10.1056/nejmoa1514616.
Reardon M.J., Van Mieghem N.M., Popma J.J., Kleiman N.S., Søndergaard L., Mumtaz M., Adams D.H., Deeb G.M., Maini B., Gada H., Chetcuti S., Gleason T., Heiser J., Lange R., Merhi W., Oh J.K., Olsen P.S., Piazza N., Williams M., Windecker S., Yakubov S.J., Grube E., Makkar R., Lee J.S., Conte J., Vang E., Nguyen H., Chang Y., Mugglin A.S., Serruys P.W., Kappetein A.P.; SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 2017; 376(14): 1321–1331, https://doi.org/10.1056/nejmoa1700456.
Thyregod H.G., Steinbrüchel D.A., Ihlemann N., Nissen H., Kjeldsen B.J., Petursson P., Chang Y., Franzen O.W., Engstrøm T., Clemmensen P., Hansen P.B., Andersen L.W., Olsen P.S., Søndergaard L. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol 2015; 65(20): 2184–2194, https://doi.org/10.1016/j.jacc.2015.03.014.
Siu S.C., Silversides C.K. Bicuspid aortic valve disease. J Am Coll Cardiol 2010; 55(25): 2789–2800, https://doi.org/10.1016/j.jacc.2009.12.068.
Yoon S.H., Bleiziffer S., De Backer O., Delgado V., Arai T., Ziegelmueller J., Barbanti M., Sharma R., Perlman G.Y., Khalique O.K., Holy E.W., Saraf S., Deuschl F., Fujita B., Ruile P., Neumann F.J., Pache G., Takahashi M., Kaneko H., Schmidt T., Ohno Y., Schofer N., Kong W.K.F., Tay E., Sugiyama D., Kawamori H., Maeno Y., Abramowitz Y., Chakravarty T., Nakamura M., Kuwata S., Yong G., Kao H.L., Lee M., Kim H.S., Modine T., Wong S.C., Bedgoni F., Testa L., Teiger E., Butter C., Ensminger S.M., Schaefer U., Dvir D., Blanke P., Leipsic J., Nietlispach F., Abdel-Wahab M., Chevalier B., Tamburino C., Hildick-Smith D., Whisenant B.K., Park S.J., Colombo A., Latib A., Kodali S.K., Bax J.J., Søndergaard L., Webb J.G., Lefèvre T., Leon M.B., Makkar R. Outcomes in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis. J Am Coll Cardiol 2017; 69(21): 2579–2589, https://doi.org/10.1016/j.jacc.2017.03.017.
Neylon A., Ahmed K., Mercanti F., Sharif F., Mylotte D. Transcatheter aortic valve implantation: status update. J Thorac Dis 2018; 10(Suppl 30): S3637–S3645, https://doi.org/10.21037/jtd.2018.10.34.
Kappetein A.P., Head S.J., Généreux P., Piazza N., van Mieghem N.M., Blackstone E.H., Brott T.G., Cohen D.J., Cutlip D.E., van Es G.A., Hahn R.T., Kirtane A.J., Krucoff M.W., Kodali S., Mack M.J., Mehran R., Rodés-Cabau J., Vranckx P., Webb J.G., Windecker S., Serruys P.W., Leon M.B.; Valve Academic Research Consortium (VARC)-2. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg 2012; 42(5): S45–S60, https://doi.org/10.1093/ejcts/ezs533.
Stangl V., Baldenhofer G., Knebel F., Zhang K., Sanad W., Spethmann S., Grubitzsch H., Sander M., Wernecke K.D., Baumann G., Stangl K., Laule M. Impact of gender on three-month outcome and left ventricular remodeling after transfemoral transcatheter aortic valve implantation. Am J Cardiol 2012; 110(6): 884–890, https://doi.org/10.1016/j.amjcard.2012.04.063.
Rymuza B., Zbroński K., Scisło P., Wilimski R., Kochman ., Ćwiek A., Filipiak K.J., Opolski G., Huczek Z. Left ventricular remodelling pattern and its relation to clinical outcomes in patients with severe aortic stenosis treated with transcatheter aortic valve implantation. Postepy Kardiol Interwencyjnej 2017; 13(4): 288–294, https://doi.org/10.5114/aic.2017.71609.
Houthuizen P., Van Garsse L.A., Poels T.T., de Jaegere P., van der Boon R.M., Swinkels B.M., Ten Berg J.M., van der Kley F., Schalij M.J., Baan J. Jr., Cocchieri R., Brueren G.R., van Straten A.H., den Heijer P., Bentala M., van Ommen V., Kluin J., Stella P.R., Prins M.H., Maessen J.G., Prinzen F.W. Left bundle-branch block induced by transcatheter aortic valve implantation increases risk of death. Circulation 2012; 126(6): 720–728, https://doi.org/10.1161/circulationaha.112.101055.
Schulz E., Jabs A., Gori T., von Bardeleben S., Hink U., Kasper-König W., Vahl C.F., Münzel T. Transcatheter aortic valve implantation with the new-generation Evolut R™: comparison with CoreValve® in a single center cohort. Int J Cardiol Heart Vasc 2016; 12: 52–56, https://doi.org/10.1016/j.ijcha.2016.06.002.
Wilczek K., Bujak K., Reguła R., Chodór P., Osadnik T. Risk factors for paravalvular leak after transcatheter aortic valve implantation. Kardiochir Torakochirurgia Pol 2015; 12(2): 89–94, https://doi.org/10.5114/kitp.2015.52848.

Ovcharenko E.A., Klyshnikov K.U., Ganyukov V.I., Shilov A.A., Vereshchagin I.E., Sizova I.N., Tarasov R.S., Barbarash L.S. Prognostic Model of Typical Complications Caused by Transcatheter Aortic Valve Replacement. Sovremennye tehnologii v medicine 2020; 12(2): 27, https://doi.org/10.17691/stm2020.12.2.03